Abstract

Highly effective neutralizing antibodies could have utility in the prevention or treatment of infection from HIV-1, malaria, and other human pathogens. Much of our work with HIV-1-neutralizing antibodies has focused on identifying, characterizing and in many case improving naturally elicited antibodies. Improved antibodies include versions of CD4-binding site-directed antibodies capable of neutralizing over 95% of HIV. Recently, we developed alterations of CD4-binding site antibodies which have increased potency and reduced polyreactivity. Other CD4-binding site antibodies are being manufactured and assessed clinically. We are also working collaboratively to identify broadly neutralizing antibodies against other highly diverse human pathogens; specifically we have also analyzed vaccinees for antibodies with broad blockade against norovirus activity and for antibodies with broadly neutralizing activity against influenza A virus, with . Thus our antibody-related work involves understanding and improving antibodies, as possible therapeutic agents against HIV-1 and other human pathogens.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIAAI005022-18
Application #
10018364
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
18
Fiscal Year
2019
Total Cost
Indirect Cost

  Institution

Name
National Institute of Allergy and Infectious Diseases
Department
Type
DUNS #
City
State
Country
Zip Code

  Publications

Zhou, Tongqing; Zheng, Anqi; Baxa, Ulrich et al. (2018) A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope. Immunity 48:500-513.e6
González, Nuria; McKee, Krisha; Lynch, Rebecca M et al. (2018) Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors. PLoS One 13:e0193773
Kwon, Young D; Chuang, Gwo-Yu; Zhang, Baoshan et al. (2018) Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody. Cell Rep 22:1798-1809
Wang, Lingshu; Shi, Wei; Chappell, James D et al. (2018) Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on MERS-CoV Spike to avoid neutralization escape. J Virol :
Dingens, Adam S; Acharya, Priyamvada; Haddox, Hugh K et al. (2018) Complete functional mapping of infection- and vaccine-elicited antibodies against the fusion peptide of HIV. PLoS Pathog 14:e1007159
Shivatare, Vidya S; Shivatare, Sachin S; Lee, Chang-Chun David et al. (2018) Unprecedented Role of Hybrid N-Glycans as Ligands for HIV-1 Broadly Neutralizing Antibodies. J Am Chem Soc 140:5202-5210
Kisalu, Neville K; Idris, Azza H; Weidle, Connor et al. (2018) A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat Med 24:408-416
Julg, Boris; Tartaglia, Lawrence J; Keele, Brandon F et al. (2017) Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Sci Transl Med 9:
Clark, Anthony J; Gindin, Tatyana; Zhang, Baoshan et al. (2017) Free Energy Perturbation Calculation of Relative Binding Free Energy between Broadly Neutralizing Antibodies and the gp120 Glycoprotein of HIV-1. J Mol Biol 429:930-947
Cale, Evan M; Gorman, Jason; Radakovich, Nathan A et al. (2017) Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop. Immunity 46:777-791.e10

Showing the most recent 10 out of 84 publications